241798-75-4Relevant academic research and scientific papers
SODIUM-HYDROGEN EXCHANGER TYPE 1 INHIBITOR CRYSTALS
-
Page 15;8, (2008/06/13)
NHE-1 inhibitors crystals, methods of using such NHE-1 inhibitor crystals and pharmaceutical compositions containing such NHE-1 inhibitor crystals. The NHE-1 inhibitor crystals are useful for the reduction of tissue damage resulting from tissue ischemia.
Ethanolates of sodium-hydrogen exchanger type-1 inhibitor
-
, (2008/06/13)
The invention relates to ethanolates of the NHE-1 inhibitor, N-(5-cyclopropyl-1-quinolin-5-yl-1H-pyrazole-4-carbonyl)-guanidine, crystalline forms of the ethanolates, methods of preparing the ethanolates, methods of treatment using the ethanolates and the mesylate salt of the NHE-1 inhibitor prepared using the ethanolates.
N-[(substituted five-membered di- or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia
-
, (2008/06/13)
NHE-1 inhibitors, methods of using such NHE-1 inhibitors and pharmaceutical compositions containing such NHE-1 inhibitors. The NHE-1 inhibitors are useful for the reduction of tissue damage resulting from tissue ischemia.
Preparation of sodium-hydrogen exchanger type-1 inhibitors
-
, (2008/06/13)
This invention relates to methods of preparing sodium-hydrogen exchanger type 1 (NHE-1) inhibitors of formula I′ 1intermediates of the NHE-1 inhibitors and a new almost colorless form of the NHE-1 inhibitor N-(5-cyclopropyl-1-quinolin-5-yl-1H-pyrazole-4-carbonyl)-guanidine.
Discovery of zoniporide: A potent and selective sodium-hydrogen exchanger type 1 (NHE-1) inhibitor with high aqueous solubility
Guzman-Perez, Angel,Wester, Ronald T.,Allen, Mary C.,Brown, Janice A.,Buchholz, Allan R.,Cook, Ewell R.,Day, Wesley W.,Hamanaka, Ernest S.,Kennedy, Scott P.,Knight, Delvin R.,Kowalczyk, Paul J.,Marala, Ravi B.,Mularski, Christian J.,Novomisle, William A.,Ruggeri, Roger B.,Tracey,Hill, Roger J.
, p. 803 - 807 (2007/10/03)
Zoniporide (CP-597,396) is a potent and selective inhibitor of NHE-1, which exhibits high aqueous solubility and acceptable pharmacokinetics for intravenous administration. The discovery, synthesis, activities, and rat and dog pharmacokinetics of this compound are presented. The potency and selectivity of zoniporide may be due to the conformation that the molecule adopts due to the presence of a cyclopropyl and a 5-quinolinyl substituent on the central pyrazole ring of the molecule.
